Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 405 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed... March 29, 2024 Experimental Drug Prevents Doxorubicin from Harming the Heart April 6, 2020 Selumetinib Continues to Show Promise in Children with NF1 June 8, 2018 Neoadjuvant Pembrolizumab Combined with Chemotherapy Followed by Adjuvant Pembrolizumab Significantly Improves... February 15, 2022 Load more HOT NEWS New obesity strategy is a ‘landmark day for the nation’s health’... Breast cancer surgery: ‘I’m proud of the tattoos inked across my... Young Mom Gives Birth To Healthy Baby Boy In The Midst... EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib
